Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.

ABSTRACT:

Background

Mortalin is enriched in a large variety of cancers and has been shown to contribute to proliferation and migration of cancer cells in multiple ways. It has been shown to bind to p53 protein in cell cytoplasm and nucleus causing inactivation of its tumor suppressor activity in cancer cells. Several other activities of mortalin including mitochondrial biogenesis, ATP production, chaperoning, anti-apoptosis contribute to pro-proliferative and migration characteristics of cancer cells. Mortalin-compromised cancer cells have been shown to undergo apoptosis in in vitro and in vivo implying that it could be a potential target for cancer therapy.

Methods

We implemented a screening of a chemical library for compounds with potential to abrogate cancer cell specific mortalin

SUBMITTER: Putri JF 

PROVIDER: S-EPMC6923857 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature